PCD market seen growing to $680 million by 2030

The Business Research Company says the primary ciliary dyskinesia market will rise from $490 million in 2025 to $530 million in 2026, with further growth expected to $680 million by 2030. The report points to gene therapy, better diagnostics and wider use of personalized medicine as key drivers.

Why it matters: - Primary ciliary dyskinesia is a rare genetic disorder, so market growth depends heavily on better diagnosis, specialized care and new treatments. - The report’s forecast signals rising commercial interest in a niche respiratory disease area that still faces low awareness and uneven diagnostic standards. - Faster development of gene therapy and stem cell approaches could expand treatment options for patients with limited current choices.

What happened: - The Business Research Company released a market report on primary ciliary dyskinesia, or PCD, on Aug. 25, 2026. - The report estimates the PCD market will grow from $0.49 billion in 2025 to $0.53 billion in 2026, a 6.7% compound annual growth rate. - The report projects the market will reach $0.68 billion by 2030, at a 6.6% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth over the next several years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also promoted a free sample of the report and the full market report.

The details: - The report says recent growth has been limited by low awareness of PCD, inconsistent diagnostic standards, reliance on traditional antibiotics, too few specialized clinics and limited use of airway clearance devices. - The report identifies gene therapy and stem cell treatments as major future growth engines. - Other growth drivers include more investment in diagnostic infrastructure, a rising prevalence of rare respiratory illnesses, wider use of personalized medicine and the integration of digital health and remote monitoring tools. - Key market trends include more genetic testing for early diagnosis, advanced imaging for monitoring, broader availability of airway clearance devices, personalized antibiotic therapy and experimental gene and stem cell treatments. - PCD disrupts the normal function and structure of cilia in the airways, ears and reproductive system. - Early diagnosis matters because targeted treatment can help manage symptoms and improve quality of life. - Gene therapy aims to correct the genetic mutations that impair ciliary motion, restore mucus clearance and reduce respiratory infections. - The American Society of Gene & Cell Therapy reported 247 gene therapy programs in Phase II clinical trials in the U.S. in the first quarter of 2023, rising to 260 by the end of the second quarter.

Between the lines: - The forecast suggests the PCD market is moving from a diagnosis-and-support model toward a more targeted treatment market. - North America’s lead likely reflects stronger research capacity and healthcare infrastructure, while Asia-Pacific’s growth points to expanding access and awareness. - The emphasis on gene therapy shows how rare-disease markets can grow when experimental pipelines start to mature, even before broad commercial adoption.

What’s next: - The market is expected to keep expanding through 2030 as gene therapy, stem cell research and diagnostic tools advance. - Wider use of genetic testing and remote monitoring could make earlier detection and longer-term disease management more common. - Growth in Asia-Pacific will likely depend on improved healthcare facilities and adoption of innovative treatments.

The bottom line: - PCD remains a small market, but better diagnostics and emerging genetic therapies are turning it into a steadier growth area.